Neuralstem, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

CUR 0.360 +0.023 (6.82%)
price chart
Neuralstem Inc (CUR) Jumps 6.82% on May 26
Neuralstem Inc (CUR) was among the biggest gainers on the Russell 2000 for Thursday May 26 as the stock popped 6.82% to $0.36, representing a gain of $0.023 per share.
Company Update (NASDAQ:CUR): Neuralstem, Inc. Announces Plan of Reorganization ...
Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced a corporate reorganization to further align the company's resources on ...
Neuralstem Reduces Workforce Across All Divisions to Cut Costs; Focus on ...  Sonoran Weekly Review
Neuralstem, Inc. (NASDAQ:CUR) Share Rating Recap
Investors may be interested in following the latest sentiment on shares of Neuralstem, Inc. (NASDAQ:CUR). In addition to monitoring sell-side analyst views, investors may also be focusing on crowd sourced data offered by individuals who watch the ...
Featured Biotech Stock: Neuralstem, Inc. (NASDAQ:CUR)
Share of Neuralstem, Inc. (NASDAQ:CUR) traded on -40.04 percent below secure line at 1:29PM EDT in order to take the company's stock at the price of $0.354.
Neuralstem, Inc. (CUR) Analyst Review  Risers & Fallers
Neuralstem Plans to Sell Shares, Warrants in Offering (NASDAQ:CUR)  Sonoran Weekly Review
Stock Update (NASDAQ:CUR): Neuralstem, Inc. Reports Fiscal First Quarter 2016 ...
Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results for the three months ended March 31, 2016 and provided ...
Neuralstem Q1 Loss Widens, Closed Public Offering (NASDAQ:CUR)  Sonoran Weekly Review
Earnings Estimates Highlight: Neuralstem (NASDAQ:CUR)  News Oracle
Stock Update (NASDAQ:CUR): Neuralstem, Inc. Announces First Patient Enrolled ...
Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that the first patient has been enrolled in the double-blind, ...
Recently Changed Price Targets On Neuralstem, Inc. (CUR)  Risers & Fallers
Stock Earnings Estimates under Consideration: Neuralstem, Inc. (NASDAQ:CUR)
Wall Street analysts are predicting that Neuralstem, Inc. (NASDAQ:CUR) will report earnings per share of $-0.06 in their quarterly report.
Latest Analyst Reports On Neuralstem, Inc.  Risers & Fallers
Tuesday Pre-Market Insights: Northwest Biotherapeutics, Inc (NWBO), Neuralstem ...
Neuralstem, Inc. (NASDAQ:CUR) is falling over 37% in pre-market trading after the company announced a proposed public offering of common stock of 20,000 shares at $0.40 per share.
Biotech Insights: Analysts Bullish On Novavax, Inc. (NVAX) And Neuralstem, Inc ...
Analysts weigh in on two biotech stocks, Novavax, Inc. (NASDAQ:NVAX) and Neuralstem, Inc. (NASDAQ:CUR) in light of recent events.
Neuralstem Inc (CUR) Drops 40.67% on May 03
Neuralstem Inc (CUR) was one of the Russell 2000's biggest losers for Tuesday May 03 as the stock slid 40.67% to $0.35, a loss of $-0.2399 per share.